You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Community Videos on Diabetes Health TV
Research with Pig Islets
Insulin (Humalog) Pen Demo
Committment to Diabetes Camps for Kids
Popular Novo Nordisk Articles
Highly Recommended Novo Nordisk Articles
In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.
0 comments - Jul 2, 2010 -
IMIDIA ("Innovative Medicines Initiative for Diabetes"), a public private consortium funded by the Innovative Medicines Initiative (IMI), announced today the launch of a project focusing on pancreatic islet cell function and survival. Academia, biotech and pharma industry have joined forces to develop biomarkers and tools to pave the way for improved disease management and ultimately provide a cure for diabetes.
0 comments - Jun 18, 2010 -
Novo Nordisk, a global healthcare company and leader in diabetes care, announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
0 comments - Apr 4, 2010 -
The U.S. Food and Drug Administration has withheld approval of Bydureon, the once-weekly version of the popular type 2 diabetes drug Byetta. The agency has asked its manufacturer, Amylin, for more information regarding Bydureon's manufacture, labeling, and risk management plan. It did not, however, request further information on tests of the drug itself-an indication that the agency probably intends to grant marketing permission once it has dotted all the i's and crossed all the t's involved in the approval process.
0 comments - Mar 29, 2010 -
The sooner people with diabetes start taking metformin, the longer the drug remains effective, according to a Kaiser Permanente study published in the March issue of Diabetes Care, a journal of the American Diabetes Association.
2 comments - Mar 12, 2010 -
Amylin Pharmaceuticals has announced that it expects to begin selling a once-weekly version of its diabetes drug, Byetta, by the end of the year. The company reports that the FDA is nearing final inspections of its manufacturing plant and could give the go-ahead for U.S. sales in early March.
2 comments - Mar 4, 2010 -
Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.
5 comments - Feb 27, 2010 -
A study commissioned by healthcare company Novo Nordisk has reported that the cost of diabetes and pre-diabetes to the U.S. economy in 2007 was $218 billion. The study, conducted by The Lewin Group, projected that by 2034, the two conditions will cost the economy $336 billion per year.
1 comment - Feb 3, 2010 -
Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve 155 British patients with type 2 diabetes. The test on human subjects, although very early-stage, puts the company in the lead to develop an oral form of a GLP-1 drug.
0 comments - Feb 1, 2010 -
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
4 comments - Jan 28, 2010 -
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.